報價延遲最少15分鐘:2025/01/11 17:59 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.97/0.16
|
|
企業價值
28.69M
|
| 資產負債 |
|
每股賬面淨值
9.07
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:59 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others. |